Journal of International Psychiatry

[Abstract] Objective: to analyze the clinical effect of luyoutai in the treatment of PSD. Methods: The 98 patients with PSD who were hospitalized in our hospital from December 2018 to August 2020 were selected and grouped by single-blind random sampling (49 cases in each group). The reference group was treated with conventional cerebrovascular disease. The experimental group was in On the basis of the reference group, Luyoutai treatment was added to compare the HAMA score, HAMD score, neurocytokine levels, monoamine transmitter metabolism, and the incidence of adverse reactions between the two groups.Results: after treatment, HAMA score and HAMD score of the experimental group were lower than those of the reference group, and the serum levels of BDNF, NGF, NE and 5-HT in the experimental group were higher than those in the reference group, and the differences were statistically significant (P < 0.05). The incidence of adverse reactions in the experimental group (8.16%) was higher than that in the control group (6.12%), P> 0.05. Conclusion: luyoutai can effectively reduce the degree of anxiety and depression in PSD patients, regulate the function of nerve cells and monoamine neurotransmitter metabolism, with less adverse reactions, which is worthy of reference.

[Key words] Lu Youtai; stroke; depression; clinical effect